Antibody-Coupled Drugs in HER2-Positive Gastric Cancer
نویسندگان
چکیده
Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic with antibody through linker. the targeting characteristics traditional cytotoxic small molecule drugs, while reducing side effects both making them kind “biological missile” and representing relatively evolving anti-cancer drugs. Antibody-coupled currently used in many solid tumors, this article reviews clinical application antibody-coupled HER2-positive gastric cancer.
منابع مشابه
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed car...
متن کاملCharacterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype
The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors lea...
متن کاملClinicopathological factors associated with HER2-positive gastric cancer
BACKGROUND The treatment of patients with advanced gastric cancer remains a most challenging task in the clinical practice. Recently, targeted therapies have significantly impacted the treatment strategy for many common malignancies. The use of trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), plus chemotherapy proved to improve med...
متن کاملMicroRNA signature for HER2-positive breast and gastric cancer.
BACKGROUND/AIM The molecular mechanism for aggressive clinical behaviour related to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) amplification is not fully-understood. In particular, little is known about microRNAs in the human epidermal growth factor receptor 2 (HER2) signaling network. PATIENTS AND METHODS Using microRNA microarray, the microRNA profiles of 16 HER...
متن کاملHER2-Positive Breast Cancer
• Objective: To review the diagnosis and management of HER2-positive breast cancer. • Methods: Qualitative review of the literature. • Results: Amplification of HER2 occurs in 20% to 25% of breast cancers and is associated with highgrade tumors that are poorly differentiated and have higher rates of recurrence. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biosciences and Medicines
سال: 2023
ISSN: ['2327-509X', '2327-5081']
DOI: https://doi.org/10.4236/jbm.2023.117002